Li Junling

Clinical Response to Gefitinib Retreatment of Lung Adenocarcinoma Patients Who Benefited from An Initial Gefitinib Therapy:A Retrospective Analysis

BACKGROUND AND OBJECTIVEnGefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC). It is most effective in women, as well as in patients who have never smoked, have pulmonary adenocarcinomas, or are of Asian origin. Several treatment options are available for NSCLC patients who responded to initial gefitinib therapy but demonstrated tumor progression, of which gefitinib readministration is the chosen therapeutic option. The present study aims to evaluate the efficacy and toxicity of gefitinib readministration.nnnMETHODSnThe clinical data of 18 patients with NSCLC who had shown partial response (PR) or achieved a stable disease (SD) status after gefitinib administration and were retreated with gefitinib due to failure of the initial therapy were reviewed and retrospectively analyzed.nnnRESULTSnOf the 18 patients studied, 1 (6%) showed partial remission (PR), 11 (61%) achieved SD, and 6 (33%) experienced disease progression. The disease control rate was 67%, and the median progression-free survival was 5.16 months (range, 1 to 24.8 months). The median overall survival from the start of the gefitinib therapy was 39.4 months (range, 15.38 to 52.44 months). Moreover, the median overall survival from the beginning of the 2nd therapy was 12.41 months (range, 3.98 to 38.24 months). Mild toxicity was observed with the 2nd gefitinib therapy.nnnCONCLUSIONnThe results of the present study indicate that patients with NSCLC may still be expected to achieve prolonged survival through gefitinib readministration if they initially responded to gefitinib and underwent various subsequent treatments.

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer

背景与目的 表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhinitor, EGFR-TKI）通过影响肿瘤的信号传导来抑制肿瘤发展，它具有良好的安全性。本研究旨在观察厄洛替尼治疗肺鳞癌患者的基本情况及生存时间。 方法 对34例使用厄洛替尼靶向治疗的肺鳞癌患者，给予厄洛替尼150 mg每日1次口服直至病情进展或因不良反应不能耐受为止。 结果 截至2016年6月13日，34例患者中一线治疗患者7例，维持治疗患者6例（其中1例因严重毒性反应停药），二线治疗患者9例（其中1例患者后续再次使用厄洛替尼），三线治疗患者5例，三线以上治疗患者7例（其中1例患者为2次使用厄洛替尼）；确认死亡患者11例。除去1例严重不良反应的患者，口服厄洛替尼后最短疾病无进展生存时间（progression-free survival, PFS）为1个月，最长PFS为55个月，中位PFS为3.5个月。 结论 对于一部分晚期不能耐受化疗或拒绝化疗，并且基因状况不明的肺鳞癌患者来说，厄洛替尼有一定疗效，绝大部分患者不良反应可耐受。

Clinical Analysis of 80 Patients with Combined Small-cell Lung Cancer

BACKGROUND AND OBJECTIVEnStudies on combined small cell lung cancer (C-SCLC), which shows continuously increasing incidence, are rare. Accordingly, we explored the relationship between the clinicopathological characteristics and prognostic factors of C-SCLC patients and analyzed the treatment of this disease.nnnMETHODSnBetween January 2006 and December 2011, 80 patients with pathologically confirmed C-SCLC were retrospectively analyzed. The Kaplan-Meier methods were used to calculate the survival rate, and the Log-rank test was used to examine differences between arms. The Cox regression model was used to analyze the independent factors affecting the overall survival (OS).nnnRESULTSnThe OS of the C-SCLC patients in all groups had a median of 26.2 mo and a range of 0.3 to 81.4 mo. In univariate analysis, gender, Karnofsky performance score before treatment, tumor diameter, and tumor stage were the considered prognostic factors affecting the OS rate of the C-SCLC patients (P<0.05). Cox multivariate analysis showed that only the TNM stage was the independent prognostic factor influencing the OS of the C-SCLC patients. The majority (75.0%) of the patients received multimodality therapy and platinum-based chemotherapy as the main treatment. However, no significant differences in OS rate were observed between patient groups under conventional SCLC regimens and non-SCLC regimens (P>0.05).nnnCONCLUSIONSnC-SCLC is a specific mixed carcinoma. Combined therapy with platinum-based chemotherapy as the main treatment should be adopted in the therapeutic regimen of this disease. TNM stage was the independent prognostic factor influencing the OS of C-SCLC patients.u2029.

[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].

BACKGROUND AND OBJECTIVEnAdvanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. This article analyzed the efficacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC.nnnMETHODSnWe retrospectively analyzed the short-term efficacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed.nnnRESULTSnAmong the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). The overall response rate was 5.9%, and the disease control rate was 47.1%. The median progression-free survival was 4.4 months (95%CI: 4.05-7.46). The main grade 3/4 toxicity was hand-foot skin reaction.nnnCONCLUSIONnSunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.